Antibody-drug conjugates (ADCs) have emerged as the primary solution for patients who have progressed on EGFR inhibitors and ...
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...
In a recent study published in the journal Nature Biotechnology, researchers in Switzerland used base and prime editing to create and analyze a wide array of variants of the epithelial growth factor ...
Evaluating activation of MAPK signaling as a potential mechanism of acquired resistance to lorlatinib in ALK-rearranged lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
7don MSN
Glowing nanoparticles exposed hidden cancer-protein behavior that could reshape drug screening
Using a powerful single-molecule imaging method they developed, a Broad Institute research team has unveiled a dynamic view ...
Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” ...
The FDA has accepted the NDA for zipalertinib to treat adult patients with locally advanced or metastatic EGFR exon 20 insertion-mutated NSCLC.
FDA NDA acceptance positions zipalertinib for post-systemic-therapy EGFR ex20ins NSCLC, with a February 27, 2027 PDUFA target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results